Floatz logo

Wellbutrin

Head and Neck Squamous Cell Carcinoma

Thomas Jefferson UniversityN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

130 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Epirubicin
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Cetuximab
Fate Therapeutics
Phase 3B
Docetaxel
National Cancer Institute (NCI)
Phase 3B

View all 50 →

Same molecule, other indications

Wellbutrin is also rated in:

Smoking CessationDormant
A
Indicative ·
82 / 100
View asset →
DysthymiaDormant
BBB
Indicative ·
73 / 100
View asset →
depressive disorderDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →